Skip to main content
Top
Published in: Clinical and Translational Oncology 8/2010

01-08-2010 | Research Articles

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias

Authors: Carolina Muriel, Emilio Esteban, Norberto Corral, Paula J. Fonseca, María Luque, José Pablo Berros, Yolanda Fernández, Pilar Blay, Joaquín Fra, Noemí Villanueva, Miguel Sanmamed, Pablo Pardo, Marta Izquierdo, José María Vieitez, Enrique Estrada, Ángel J. Lacave

Published in: Clinical and Translational Oncology | Issue 8/2010

Login to get access
Metadata
Title
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias
Authors
Carolina Muriel
Emilio Esteban
Norberto Corral
Paula J. Fonseca
María Luque
José Pablo Berros
Yolanda Fernández
Pilar Blay
Joaquín Fra
Noemí Villanueva
Miguel Sanmamed
Pablo Pardo
Marta Izquierdo
José María Vieitez
Enrique Estrada
Ángel J. Lacave
Publication date
01-08-2010
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 8/2010
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-010-0554-0

Other articles of this Issue 8/2010

Clinical and Translational Oncology 8/2010 Go to the issue

News and Views/The Journalist Corner

Health and well-being

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine